MedTrace Logo

Bismuth Improves the Efficacy of Levofloxacin-containing Triple Therapy for Helicobacter Pylori Treatment

NCT01667718 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 161

Last updated 2012-12-13

No results posted yet for this study

Summary

To examine and compare the efficacy of 2 week Levofloxacin-containing therapies with and without Bismuth for H.pylori treatment.

Conditions

  • Functional Dyspepsia
  • Peptic Ulcer

Interventions

DRUG

Bismuth

Bismuth 220mg b.i.d for 2 weeks

DRUG

Lansoprazole

Lansoprazole 30 mg b.i.d.for 2 weeks

DRUG

Levofloxacin

Levofloxacin 0.5 q.d. for 2 weeks

DRUG

Amoxicillin

Amoxicillin 1 g b.i.d. for 2 weeks

Sponsors & Collaborators

  • Shanghai Jiao Tong University School of Medicine

    lead OTHER

Principal Investigators

  • Hong Lu · Shanghai Jiao-Tong University School of Medicine Renji Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2012-10-31
Completion
2012-10-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01667718 on ClinicalTrials.gov